New dosing strategy aims to protect more people from severe food allergies
NCT ID NCT06943534
Summary
This study is testing if a higher, weight-based dose of the drug omalizumab is safe and effective for people with multiple food allergies. It aims to help participants better tolerate accidental exposures to foods like peanut, milk, or egg. The trial includes people who have been excluded from standard dosing due to high levels of a specific allergic antibody.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOOD ALLERGY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of North Carolina at Chapel Hill
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact Email: •••••@•••••
-
University of Texas Southwestern
RECRUITINGDallas, Texas, 75390, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.